Navigation Links
TB Alliance Names Elana Robertson Senior Vice President, Market Access
Date:7/31/2014

NEW YORK, July 31, 2014 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing better, faster and affordable treatments for tuberculosis (TB), announced the appointment of Elana Robertson to Senior Vice President, Market Access. Ms. Robertson joins the organization from Novartis Vaccines, where she was responsible for the company's business in Sub-Saharan Africa and Eastern Europe. In her new role, she will oversee the TB Alliance's efforts to ensure beneficial new TB treatments are available and adopted around the globe, particularly in countries with the highest rates of the disease.

"We are on the cusp of realizing improved treatments to fight tuberculosis—but we can't achieve our mission until those treatments reach people in need," said Mel Spigelman, MD, President and CEO of the TB Alliance. "With her experience heading market expansion efforts in nations with high rates of TB infection, Elana Robertson is the right person to guide that effort."

Ms. Robertson has more than 20 years of experience in the pharmaceutical industry, where she has been responsible for the marketing and commercialization of vaccines and drugs on a global, regional and country level. For the past six years, she served as Head of Sub-Saharan Africa and Other Eastern Europe for Novartis Vaccines, where she was responsible for expanding the company's business in those regions. Prior to joining Novartis, Ms. Robertson held business development, marketing, sales and product management positions at several other pharmaceutical companies, including Roche, Sanofi Pasteur, Schering Plough, Upjohn and Intramed. A native of South Africa, she holds undergraduate and graduate degrees from Stellenbosch University, a marketing diploma from Damelin College, and is pursuing a master's degree in public health from the University of Liverpool in England.

"I've seen the devastation caused by tuberculosis first hand in my home country of South Africa and the burden the current treatments cause on the healthcare system and on patients," said Elana Roberston. "I am excited to join the global fight against this deadly disease by ensuring new drugs, which hold the potential to improve the lives of millions, are available to those in need."

Before joining the pharmaceutical industry, Ms. Robertson was a Lecturer in Physiology at the University of Witwatersrand and a researcher at the University of Stellenbosch.

Every year, 1.3 million people worldwide die from TB. It is estimated that the bacteria that causes TB infects one-third of the world's population. The current treatment is inadequate, and resistance to today's drugs is growing. New, faster-acting, simpler drug regimens are critical to defeating TB.

About the TB Alliance

The Global Alliance for TB Drug Development (TB Alliance) is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. The TB Alliance operates with funding from Australia Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, European Commission, Global Health Innovative Technology Fund, Irish Aid, National Institute of Allergy and Infectious Disease, UNITAID, United Kingdom Department for International Development, United States Agency for International Development, and the United States Food and Drug Administration. For more information, please visit tballiance.org.

Contact:
Joanna Breitstein, +1 646-616-8613 or joanna.breitstein@tballiance.org

Photo - http://photos.prnewswire.com/prnh/20140730/131788


'/>"/>
SOURCE TB Alliance
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
3. PDR and the iHealth Alliance Announce New Drug Safety Certification for EHRs
4. Physician-Patient Alliance for Health & Safety: Monitoring Technology for PCA Pumps Can Prevent Adverse Events: So Why Are Hospitals Not Using It?
5. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
6. UBM Canon, the Global MedTech Authority, Announces Strategic Alliance with ITG Market Research, a Preeminent Industry Research Organization
7. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
8. Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Sign Strategic Alliance to Further Cancer Research
9. Premier healthcare alliance honors Atrium Medical Corporation for operational excellence
10. Nonin Medicals Tissue Oximetry System Recognized at Premier Healthcare Alliance Innovation Celebration
11. The UCB-Harvard Research Alliance Expands and Moves Forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... York , March 29, 2017 ... published a report, which provides an exhaustive study ... the study, nearly 242 companies are functional in ... and competitive. With the leading companies, such as ... Pharma LP, focusing aggressively on various marketing strategies ...
(Date:3/29/2017)... 2017  The Pharmaceutical Care Management Association (PCMA) today ... on patient out-of-pocket spending: ... (CMS), the average amount spent out-of-pocket for drugs continues ... in 2016, down from 23% in 2006. ... a coverage problem. Health plans don,t have unlimited funds ...
(Date:3/29/2017)... Calif. , March 29, 2017  Designers of ... significantly reduce solution size by 50% and extend battery ... ) power management integrated circuit (PMIC) from Maxim Integrated ... PMIC supports a low input voltage of just 0.7V ... Air and Silver Oxide, as well as the more ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
(Date:3/29/2017)... Minn. (PRWEB) , ... March 29, 2017 , ... ... medical office buildings (MOBs) and other outpatient facilities, and who are the most ... exclusively at those questions, Revista and Healthcare Real Estate Insights (HREI) found that ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... with wearing oral braces. "The rubber bands used in conjunction with my braces ... I decided to design a way to prevent this problem." The O.B.S. was ...
(Date:3/29/2017)... ... 29, 2017 , ... Immunotherapy has emerged as one of the most promising ... to be the next revolution in our fight against this complex disease. One of ... immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single ...
(Date:3/29/2017)... ... March 29, 2017 , ... Physicians’ Education Resource® (PER®), will ... education conference for clinicians who manage some of the most difficult-to-treat forms of ... The program will be led by co- chairs Dr. John Marshall, chief of ...
Breaking Medicine News(10 mins):